**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 45968

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma**

Takaya H *et al*.ADAMTS13 and von Willebrand factor as biomarkers

Hiroaki Takaya, Tadashi Namisaki, Naotaka Shimozato, Kosuke Kaji, Mitsuteru Kitade, Kei Moriya, Shinya Sato, Hideto Kawaratani, Takemi Akahane, Masanori Matsumoto, Hitoshi Yoshiji

**Hiroaki Takaya, Tadashi Namisaki, Naotaka Shimozato, Kosuke Kaji, Mitsuteru Kitade, Kei Moriya, Shinya Sato, Hideto Kawaratani, Takemi Akahane, Hitoshi Yoshiji,**Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8522, Japan

**Masanori Matsumoto,** Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara 634-8522, Japan

**ORCID number:** Hiroaki Takaya (0000-0002-4990-7573); Tadashi Namisaki (0000-0002-3158-5318); Naotaka Shimozato (0000-0002-7558-4165); Kosuke Kaji (0000-0002-1822-6759); Mitsuteru Kitade (0000-0001-7592-7589); Kei Moriya (0000-0002-2878-8296); Shinya Sato (0000-0003-3049-3443); Hideto Kawaratani (0000-0002-4361-0592); Takemi Akahane (0000-0002-6675-0475); Masanori Matsumoto (0000-0002-7243-3126); Hitoshi Yoshiji (0000-0002-5243-8544).

**Author contributions:** Takaya H, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T and Matsumoto M performed data analysis; Takaya H, Namisaki T and Yoshiji H contributed to the writing of the manuscript.

**Institutional review board statement:** Informed consent for the use of resected tissue was obtained from all patients and the study protocol was approved by the Ethics Committee of Nara Medical University.

**Informed consent statement:** All study participants or their legal guardians provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** **Hiroaki Takaya, MD, PhD, Assistant Professor,** Third Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara 6348522, Japan. htky@naramed-u.ac.jp

**Telephone:** +81-744-223051

**Fax:** +81-744-247122

**Received:** January 30, 2019

**Peer-review started:** February 14, 2019

**First decision:** March 14, 2019

**Revised:** March 26, 2019

**Accepted:**April 8, 2019

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

Many advanced hepatocellular carcinoma (HCC) patients are receiving sorafenib treatment. Sorafenib reportedly improves overall survival (OS) significantly in patients with HCC. Prediction of sorafenib response and prognosis in patients with HCC receiving sorafenib treatment are important due to the potentially serious side effects of sorafenib. A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) and von Willebrand factor (VWF) are associated with the pathophysiology of liver cirrhosis and HCC through their roles in hypercoagulability; they are also associated with angiogenesis *via* vascular endothelial growth factor (VEGF). The imbalance between ADAMTS13 and VWF was associated with prognosis of various cancers in patients undergoing chemotherapy.

***AIM***

To investigate ADAMTS13 and VWF as potential biomarkers for sorafenib response and prognosis in patients with HCC receiving sorafenib treatment.

***METHODS***

Forty-one patients with HCC receiving sorafenib treatment were included in this study. The initial daily sorafenib dose was 400 mg in all patients. ADAMTS13 activity (ADAMTS13:AC), VWF antigen (VWF:Ag), VEGF levels were determined by enzyme-linked immunosorbent assay. Univariate and multivariate analyses were used to determine predictive factors for sorafenib response and prognosis in patients with HCC receiving sorafenib treatment.

***RESULTS***

ADAMTS13:AC was significantly higher in patients with stable disease (SD), partial response (PR), and complete response (CR) than in those with progressive disease (PD) (*P <* 0.05). In contrast, VWF:Ag and the VWF:Ag/ADAMTS13:AC ratio were significantly lower in patients with SD, PR, and CR than in those with PD (*P <* 0.05 for both). Multivariate analysis showed that the VWF:Ag/ADAMTS13:AC ratio was the only predictive factor for sorafenib response and ADAMTS13:AC was the only prognostic factor in patients with HCC receiving sorafenib treatment. The patients with a low ADAMTS13:AC (< 78.0) had significantly higher VEGF levels than those with a high ADAMTS13:AC (≥ 78.0) (*P <* 0.05).

***CONCLUSION***

The VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC are potentially useful biomarkers for sorafenib response and prognosis, respectively, in patients with HCC receiving sorafenib treatment.

**Key words**: ADAMTS13; Von Willebrand factor; Biomarkers; Hepatocellular carcinoma; Sorafenib

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** There is an urgent clinical need to prediction of sorafenib response and prognosis in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment due to the potentially serious side effects of sorafenib in these patients. Multivariate analysis showed that the von Willebrand factor (VWF) antigen (VWF:Ag)/a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) activity (ADAMTS13:AC) ratio was the only predictive factor for sorafenib response and ADAMTS13:AC was the only prognostic factor in patients with HCC receiving sorafenib treatment. The VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC are potentially useful biomarkers for sorafenib response and prognosis, respectively, in patients with HCC receiving sorafenib treatment.

Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. *World J Gastrointest Oncol* 2019; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second most common cause of cancer-related deaths worldwide[1,2]. In Japan, medical treatment policies for HCC are based on the consensus-based clinical practice guidelines for HCC management set by the Japan Society of Hepatology (JSH)[3], which recommend that patients with HCC who cannot undergo liver resection, radiofrequency ablation, or transcatheter arterial chemoembolization (TACE) should be considered to receive molecularly targeted drugs including sorafenib[3]. Sorafenib is a small inhibitor of several tyrosine protein kinases, including vascular endothelial growth factor (VEGF) receptor, platelet derived growth factor (PDGF) receptor, and Raf family kinases[4]. Sorafenib was shown to significantly improve overall survival (OS) in patients with HCC[4]. It is important to predict response to sorafenib and prognosis of HCC patients treated with sorafenib to avoid ineffective treatments because sorafenib has various side effects including hand-foot syndrome.

A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) is a metalloproteinase that specifically cleaves multimeric von Willebrand factor (VWF) between Tyr1605 and Met1606 residues in the A2 domain[5-8]. ADAMTS13 is produced exclusively in hepatic stellate cells adjacent to endothelial cells[9]. VWF is synthesized in vascular endothelial cells and released into plasma as unusually large VWF multimers[10]. In the presence of an imbalance between ADAMTS13 and VWF, VWF multimers are cleaved improperly, leading to their accumulation and induction of platelet thrombus formation under high-shear stress in microvessels[11].

We previously reported that the imbalance of ADAMTS13 and VWF was associated with the pathophysiology of liver cirrhosis (LC) and HCC[8,12,13], suggesting that LC and HCC might be related to hypercoagulability[8,12,13]. Previous studies have reported that the imbalance of ADAMTS13 and VWF is associated with angiogenesis through VEGF[14-17], which in turn is associated with LC and HCC development[18-20]. In addition, the imbalance of ADAMTS13 and VWF might be associated with sorafenib treatment efficiency because VEGF is inhibited by sorafenib[4]. Furthermore, blood coagulation cascade was demonstrated to be related to cancer development[21,22}, indicating that the imbalance of ADAMTS13 and VWF is associated with hypercoagulability as well as cancer development[23]. Recent studies have also reported that the imbalance between ADAMTS13 and VWF was associated with prognosis of various cancers in patients undergoing chemotherapy including molecularly targeted drugs[24].

In the current study, we investigated the relationship between plasma ADAMTS13 and VWF levels in patients with HCC receiving sorafenib treatment and determined whether plasma ADAMTS13 and VWF levels were useful biomarkers for prediction of sorafenib response and prognosis of HCC in patients with HCC receiving sorafenib treatment.

**MATERIALS AND METHODS**

***Patients***

There were 44 patients with HCC who were initiated on sorafenib treatment from December 2012 to November 2017 at our hospital. After excluding three patients who discontinued sorafenib treatment in the first month, 41 patients were included in this study. The initial daily sorafenib dose was 400 mg in all patients, and sorafenib therapy are based on the JSH consensus-based clinical practice guidelines for the management of HCC[3]. All patients underwent dynamic computed tomographic scanning or dynamic magnetic resonance imaging before sorafenib treatment, at 1 mo after starting sorafenib treatment, and every 3 mo thereafter. Radiologic response to therapy was evaluated according to modified response evaluation criteria in solid tumors[25]. Tumor-node-metastasis (TNM) stage was evaluated according to the TNM classification of the Union for the International Cancer Control of malignant tumors. No patient had infection, uncontrolled ascites, uncontrolled hepatic encephalopathy, or uncontrolled gastroesophageal varices. This study was approved by the local ethics committee of Nara Medical University and performed in accordance with the ethical standards stated in the Declaration of Helsinki. Informed consent was obtained from all participants included in the study.

***Determination of ADAMTS13 activity and VWF antigen levels***

Blood samples were collected from all patients at the time of admission, during their hospital stay or during regular outpatient treatment within 1 mo before sorafenib treatment initiation. The samples were stored in plastic tubes containing 0.38% v/v sodium citrate. Platelet-poor plasma, which was prepared by centrifuging the samples at 3000 *g* at 4 ℃ for 15 min, was stored as aliquots at −80 ℃ until analysis. Plasma ADAMTS13 activity (ADAMTS13:AC) was determined by a sensitive chromogenic enzyme-linked immunosorbent assay (Kainos Laboratories, Tokyo, Japan)[26]. Mean normal ADAMTS13:AC level was 99% ± 22%. Plasma VWF antigen (VWF:Ag) was measured by sandwich enzyme-linked immunosorbent assay using a rabbit anti-human VWF polyclonal antiserum (Dako, Glostrup, Denmark). Mean normal VWF:Ag level was 102% ± 33%[27].

***Measurement of VEGF and VEGFR-2 levels***

VEGF and VEGF receptor 2 (VEGFR-2) levels were determined by commercially available immunoassay kits (RayBiotech, United States, and R and D Systems, United States, respectively). The detection limits for VEGF and VEGFR-2 were 10 and 11.4 pg/mL, respectively.

***Statistical analysis***

Differences between groups were analyzed using the Mann–Whitney *U*-test, and correlations were calculated with Spearman’s rank test. Categorical data were analyzed using Fisher’s exact test. Univariate and multivariate analyses were performed for predictive and prognostic factors for sorafenib treatment in HCC. Logistic regression analysis with stepwise selection of variables was performed to determine independent predictive factors of sorafenib treatment for HCC, and the Cox proportional hazards regression analysis with stepwise selection of variables was conducted to determine independent prognostic factors of sorafenib treatment for HCC. Progression-free survival (PFS) and OS curves were calculated using the Kaplan–Meier method, and differences between groups were assessed using the log-rank test. Data were expressed as medians with interquartile ranges. A two-tailed *P* value of less than 0.05 was considered statistically significant. Analyses were performed using EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0). Specifically, EZR is a modified version of R commander (version 1.6-3) that includes statistical functions that are frequently used in biostatistics[28].

**RESULTS**

***Clinical characteristics of the patients***

The patient characteristics are shown in Table 1. The median age of patients with HCC was 74.0 (69.0–81.0) years. The study population comprised 38 males and three females. Among these, 7, 20, 3, and 11 patients had hepatitis B virus, hepatitis C virus, non-alcoholic steatohepatitis, and alcohol abuse, respectively. The median maximum tumor size was 3.3 (2.5–7.7) cm. In this cohort, 3, 2, 1, and 33 patients had 1, 2, 3, and ≥ 4 tumors, respectively, whereas two patients had only distant metastases. Portal vein tumor thrombosis and distant metastasis were present in 7 and 17 patients, respectively. Serum levels of alpha-fetoprotein (AFP), des-γ-carboxy prothrombin (DCP), *lens* *culinaris* agglutinin-reactive fraction of AFP (AFP-L3%), VEGF, and VEGFR-2 were 121.8 (11.3–2611.0) ng/mL, 359.5 (58.0–5277.5) mAU/mL, 13.2 (1.7–42.4)%, 25.8 (14.1–40.1) pg/mL, and 6500 (5750–7400) pg/mL, respectively. DCP was directly correlated with VEGF (*r* = 0.503, *P <* 0.05). However, DCP was not correlated with VEGFR-2, and AFP or AFP-L3% was not correlated with VEGF or VEGFR-2. In the current study cohort, there were no differences in the characteristics of patients with stable disease (SD), partial response (PR), and complete response (CR) compared with those with progressive disease (PD), except the DCP levels and observation (survival) period.

***Plasma ADAMTS13:AC and VWF:Ag level in patients with HCC receiving sorafenib treatment***

ADAMTS13:AC level was significantly higher in patients with HCC who had SD, PR, and CR than those with PD (*P <* 0.05) (Figure 1A). In contrast, VWF:Ag and the VWF:Ag/ADAMTS13:AC ratio levels were significantly lower in those with SD, PR, and CR than those with PD (*P <* 0.05 for both) (Figure 1B and C). ADAMTS13:AC level was directly correlated with albumin (*r* = 0.457, *P <* 0.05), and VWF:Ag and the VWF:Ag/ADAMTS13:AC ratio levels were directly correlated with total bilirubin(*r* = 0.329, *P <* 0.05 and *r* = 0.316, *P <* 0.05, respectively). In addition, the patients were categorized into two, according to the TNM stage (TNM stage 2 and 3 is 21 patients, and TNM stage 4 is 20 patients). The VWF:Ag/ADAMTS13:AC ratio levels was higher in patients with TNM stage 4 HCC than those with TNM stage 2 and 3 HCC (Figure 2).

***Predictive factors*** ***for sorafenib response***

ADAMTS13:AC and the VWF:Ag/ADAMTS13:AC ratio were associated with sorafenib response in univariate analysis (Table 2). To determine predictive factors for sorafenib response, we performed multivariate analysis using albumin, DCP, VEGF, maximum tumor size, distant metastasis, ADAMTS13:AC, VWF:Ag, and the VWF:Ag/ADAMTS13:AC ratio, which had *P*-values of < 0.2 in the univariate analysis. The VWF:Ag/ADAMTS13:AC ratio was significantly associated with sorafenib response in multivariate analysis (Table 2). The receiver operating characteristic (ROC) analysis revealed that a cutoff VWF:Ag/ADAMTS13:AC ratio of 2.609 had a specificity of 84.2% and a sensitivity of 88.2%, and the area under the ROC curve (AUC) was 0.836 (Figure 3). Next, the study patients were categorized into two groups according to the ROC cutoff VWF:Ag/ADAMTS13:AC ratio: low (VWF:Ag/ADAMTS13:AC ratio < 2.609) and high (VWF:Ag/ADAMTS13:AC ratio ≥ 2.609). The patients with a high VWF:Ag/ADAMTS13:AC ratio had significantly higher VEGF levels than those with a low VWF:Ag/ADAMTS13:AC ratio (Figure 4A), indicating that the VWF:Ag/ADAMTS13:AC ratio might be associated with VEGF in patients with HCC. However, the patients with VEGFR-2, AFP, DCP and AFP-L3% levels were not different between the low and high VWF:Ag/ADAMTS13:AC ratio groups.

***Prognostic factors for patients with HCC receiving sorafenib treatment***

In univariate analysis, age, DCP, and ADAMTS13:AC were associated with prognosis in patients with HCC receiving sorafenib treatment (Table 3). To determine prognostic factors in patients with HCC receiving sorafenib treatment, we performed multivariate analysis using age, sex, DCP, tumor number, ADAMTS13:AC, and the VWF:Ag/ADAMTS13:AC ratio, which had *P*-values < 0.2 in the univariate analysis. ADAMTS13:AC was associated significantly with prognosis in multivariate analysis (Table 3). Therefore, the patients were categorized into two groups according to the median cutoff ADAMTS13:AC: low (ADAMTS13:AC < 78.0) and high (ADAMTS13:AC ≥ 78.0). The patients with a high ADAMTS13:AC had significantly longer PFS and OS than those with a low ADAMTS13:AC (Figure 5). The patients with a low ADAMTS13:AC had significantly higher VEGF levels than those with a high ADAMTS13:AC (Figure 4B). These results indicated that ADAMTS13:AC might be associated with VEGF in patients with HCC. However, the patients with VEGFR-2, AFP, DCP, and AFP-L3% levels were not different between the low and high ADAMTS13:AC groups.

**DISCUSSION**

The results of the present study suggest that the VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC are potential biomarkers for sorafenib response and prognosis, respectively, in patients with HCC receiving sorafenib treatment. Previous studies reported that Child-Pugh score A patients with HCC receiving sorafenib treatment had longer OS and PFS than those with Child-Pugh score B patients[29] and that VWF:Ag was associated with prognosis in cirrhotic patients[30]. Furthermore, we previously reported that ADAMTS13:AC and VWF:Ag were associated with functional liver capacity[12,13] and that ADAMTS13:AC was associated with prognosis in cirrhotic patients[6]. In other words, ADAMTS13:AC and VWF:Ag are useful biomarkers to evaluate functional liver capacity in detail for cirrhotic patients[6,30]. As the result, the VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC might be associated with sorafenib response and prognosis, respectively, in patients with HCC receiving sorafenib treatment.

A recent study reported that HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage B receiving sorafenib treatment had longer OS than those with BCLC stage C[29]. The current study revealed that the VWF:Ag/ADAMTS13:AC ratio was associated with TNM stage in HCC. Furthermore, several studies reported that the VWF:Ag/ADAMTS13:AC ratio was associated with TNM stage and prognosis in various cancers[24,31,32]. The association of the VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC with sorafenib response and prognosis, respectively, in patients with HCC receiving sorafenib treatment reflects that the ADAMTS13–VWF imbalance might be associated with tumor stage. Furthermore, this may be caused by blood coagulation cascade associated with cancer development[21,22] because the ADAMTS13–VWF imbalance associated with blood coagulation cascade[11].

In addition, angiogenesis plays an important role in LC and HCC development, which are related to VEGF, as VEGF levels are increased in patients with LC and HCC[18-20]. Recent studies reported that VWF reduced VEGF-depend angiogenesis via multiple intracellular and extracellular pathways involving integrin avβ3 and angiopoietin-2[14-16] and that ADAMTS13 induced angiogenesis by ADAMTS13-mediated cleavage of VWF and ADAMTS13-mediated VEGFR-2 phosphorylation, which lead to enhanced VEGF expression[17]. Xu *et* *al*[16] revealed the critical role of the balance between ADAMTS13 and VWF in regulating blood vessel formation. Furthermore, we observed that VWF:Ag was a predictive factor[8] and that the VWF:Ag/ADAMTS13:AC ratio was a diagnostic factor (unpublished observations) for HCC in cirrhotic patients. As sorafenib inhibits VEGF and the change in VEGF during sorafenib treatment is associated with the prognosis of patients with HCC receiving sorafenib treatment[4], the VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC might be associated sorafenib response and prognosis, respectively, in patients with HCC receiving sorafenib treatment, through angiogenesis. In fact, in the present study, we also found that the VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC were associated with VEGF levels.

Furthermore, antiplatelet therapy inhibits PDGF, which induces HCC development[33]. Recent studies reported that antiplatelet therapy prevented HCC development in cirrhotic patients[34] and improved survival in a mouse model of chronic hepatitis B[33]. An imbalance between ADAMTS13 and VWF induces platelet thrombus formation[11] and thereby is possibly associated with PDGF. The association of the VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC with sorafenib response and prognosis in patients with HCC receiving sorafenib treatment might be occurring via PDGF, which is inhibited by sorafenib and VEGF. The relationship of the ADAMTS13-VWF imbalance with angiogenic factors requires further investigation.

There are several promising candidate biomarkers for predicting sorafenib response and prognosis in patients with HCC receiving sorafenib treatment, including VEGF-A, angiopoietin-2, insulin-like growth factor-1, and neutrophil/lymphocyte ratio[29,35], most of which are not identified as biomarkers for these patients due to high costs and limited practicality in a clinical setting[29,35]. In addition, while these biomarkers were reported as prognostic factors for OS in patients with HCC receiving sorafenib treatment, their relationship with PFS was not determined. Importantly, OS is affected by after-treatment. In fact, in the present study, several patients underwent TACE and/or hepatic arterial infusion chemotherapy using cisplatin. Therefore, we propose that PFS might be more important than OS for evaluating sorafenib treatment efficiency in patients with HCC in clinical setting. Because ADAMTS13:AC is a prognostic factor for OS and PFS in patients with HCC receiving sorafenib treatment, we believe that ADAMTS13:AC is a more useful biomarker than other biomarkers.

The present study has several limitations, including a short observation period and the small sample size. Cirrhotic patients with HCC occasionally develop thrombosis or inflammation, including portal thrombosis and bacterial overgrowth and translocation, which may impact the VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC and impact their value as biomarkers. In addition, only 7.3% of patients were female (male: 38, female: 3). We believe that the difference in gender had no effects in our study because a previous study has reported that the relationships between ADAMTS13:AC and other parameters (*e.g.*, albumin, total bilirubin, aspartate aminotransferase, alkaline phosphatase, and creatinine) are not associated with gender bias[36].

In summary, the VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC, which were associated with VEGF, were independent predictive factors for sorafenib response and prognosis, respectively, in patients with HCC receiving sorafenib treatment. To our knowledge, this is the first report the ADAMTS13-VWF imbalance in association with sorafenib response and prognosis in patients with HCC receiving sorafenib treatment.

**ARTICLE HIGHLIGHTS**

***Research background***

Sorafenib reportedly improves overall survival (OS) significantly in patients with HCC. Prediction of sorafenib response and prognosis in patients with HCC receiving sorafenib treatment are important due to the potentially serious side effects of sorafenib.

***Research motivation***

A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) and von Willebrand factor (VWF) are associated with the pathophysiology of liver cirrhosis and HCC through their roles in hypercoagulability; they are also associated with angiogenesis via vascular endothelial growth factor (VEGF). The imbalance between ADAMTS13 and VWF was associated with prognosis of various cancers in patients undergoing chemotherapy.

***Research objectives***

To investigate ADAMTS13 and VWF as potential biomarkers for sorafenib response and prognosis in patients with HCC receiving sorafenib treatment.

***Research methods***

Forty-one patients with HCC receiving sorafenib treatment were included in this study. The initial daily sorafenib dose was 400 mg in all patients. ADAMTS13 activity (ADAMTS13:AC), VWF antigen (VWF:Ag), VEGF levels were determined by enzyme-linked immunosorbent assay. Univariate and multivariate analyses were used to determine predictive factors for sorafenib response and prognosis in patients with HCC receiving sorafenib treatment.

***Research results***

Multivariate analysis showed that the VWF:Ag/ADAMTS13:AC ratio was the only predictive factor for sorafenib response and ADAMTS13:AC was the only prognostic factor in patients with HCC receiving sorafenib treatment. The patients with a low ADAMTS13:AC (< 78.0) had significantly higher VEGF levels than those with a high ADAMTS13:AC (≥ 78.0) (P < 0.05).

***Research conclusions***

The VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC are potentially useful biomarkers for sorafenib response and prognosis, respectively, in patients with HCC receiving sorafenib treatment.

***Research perspectives***

This is the first report the ADAMTS13-VWF imbalance in association with sorafenib response and prognosis in patients with HCC receiving sorafenib treatment.

**ACKNOWLEDGMENTS**

This work was completed with the help of Ms. Yoshie Nakai, Professor Hiroshi Fukui, and Professor Masahito Uemura.

**REFERENCES**

1 **Llovet JM**, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. *Nat Rev Dis Primers* 2016; **2**: 16018 [PMID: 27158749 DOI: 10.1038/nrdp.2016.18]

2 **Zhu RX**, Seto WK, Lai CL, Yuen MF. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. *Gut Liver* 2016; **10**: 332-339 [PMID: 27114433 DOI: 10.5009/gnl15257]

3 **Kudo M**, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; Liver Cancer Study Group of Japan. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. *Liver Cancer* 2014; **3**: 458-468 [PMID: 26280007 DOI: 10.1159/000343875]

4 **Tsuchiya K**, Asahina Y, Matsuda S, Muraoka M, Nakata T, Suzuki Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. *Cancer* 2014; **120**: 229-237 [PMID: 24122122 DOI: 10.1002/cncr.28384]

5 **Takaya H**, Kawaratani H, Kubo T, Seki K, Sawada Y, Kaji K, Okura Y, Takeda K, Kitade M, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H. Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis. *Hepatol Res* 2018; **48**: E52-E60 [PMID: 28628948 DOI: 10.1111/hepr.12926]

6 **Takaya H**, Uemura M, Fujimura Y, Matsumoto M, Matsuyama T, Kato S, Morioka C, Ishizashi H, Hori Y, Fujimoto M, Tsujimoto T, Kawaratani H, Toyohara M, Kurumatani N, Fukui H. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score. *Hepatol Res* 2012; **42**: 459-472 [PMID: 22292786 DOI: 10.1111/j.1872-034X.2011.00950.x]

7 **Takaya H**, Yoshiji H, Kawaratani H, Sakai K, Matsumoto M, Fujimura Y, Fukui H. Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure. *Biomed Rep* 2017; **7**: 277-285 [PMID: 28894574 DOI: 10.3892/br.2017.945]

8 **Takaya H**, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H. von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. *United European Gastroenterol J* 2018; **6**: 1401-1409 [PMID: 30386613 DOI: 10.1177/2050640618779660]

9 **Uemura M**, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H, Fujimura Y. Localization of ADAMTS13 to the stellate cells of human liver. *Blood* 2005; **106**: 922-924 [PMID: 15855280 DOI: 10.1182/blood-2005-01-0152]

10 **Moake JL**, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. *J Clin Invest* 1986; **78**: 1456-1461 [PMID: 3491092 DOI: 10.1172/JCI112736]

11 **Furlan M**, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. *N Engl J Med* 1998; **339**: 1578-1584 [PMID: 9828245 DOI: 10.1056/NEJM199811263392202]

12 **Uemura M**, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H. Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis. *Int J Hepatol* 2011; **2011**: 759047 [PMID: 21994870 DOI: 10.4061/2011/759047]

13 **Uemura M**, Fujimura Y, Matsumoto M, Ishizashi H, Kato S, Matsuyama T, Isonishi A, Ishikawa M, Yagita M, Morioka C, Yoshiji H, Tsujimoto T, Kurumatani N, Fukui H. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. *Thromb Haemost* 2008; **99**: 1019-1029 [PMID: 18521503 DOI: 10.1160/TH08-01-0006]

14 **Marisi G**, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? *World J Gastroenterol* 2018; **24**: 4152-4163 [PMID: 30271080 DOI: 10.3748/wjg.v24.i36.4152]

15 **Kalambokis GN**, Oikonomou A, Christou L, Kolaitis NI, Tsianos EV, Christodoulou D, Baltayiannis G. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. *J Hepatol* 2016; **65**: 921-928 [PMID: 27297911 DOI: 10.1016/j.jhep.2016.06.002]

16 **Tabernero J**, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. *Lancet Oncol* 2015; **16**: 937-948 [PMID: 26184520 DOI: 10.1016/S1470-2045(15)00138-2]

17 **Salum GM**, Bader El Din NG, Ibrahim MK, Anany MA, Dawood RM, Khairy A, El Awady MK. Vascular Endothelial Growth Factor Expression in Hepatitis C Virus-Induced Liver Fibrosis: A Potential Biomarker. *J Interferon Cytokine Res* 2017; **37**: 310-316 [PMID: 28472595 DOI: 10.1089/jir.2016.0127]

18 **Sergio A**, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. *Am J Gastroenterol* 2008; **103**: 914-921 [PMID: 18177453 DOI: 10.1111/j.1572-0241.2007.01712.x]

19 **Yoshiji H**, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Masaki T, Fukui H. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. *Hepatology* 2004; **39**: 1517-1524 [PMID: 15185292 DOI: 10.1002/hep.20218]

20 **Starke RD**, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD, Cutler DF, Laffan MA, Randi AM. Endothelial von Willebrand factor regulates angiogenesis. *Blood* 2011; **117**: 1071-1080 [PMID: 21048155 DOI: 10.1182/blood-2010-01-264507]

21 **Lenting PJ**, Casari C, Christophe OD, Denis CV. von Willebrand factor: the old, the new and the unknown. *J Thromb Haemost* 2012; **10**: 2428-2437 [PMID: 23020315 DOI: 10.1111/jth.12008]

22 **Randi AM**. Angiogenesis and the ADAMTS13-VWF balance. *Blood* 2017; **130**: 1-2 [PMID: 28684444 DOI: 10.1182/blood-2017-05-781260]

23 **Lee M**, Keener J, Xiao J, Long Zheng X, Rodgers GM. ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2. *Cell Mol Life Sci* 2015; **72**: 349-356 [PMID: 24950743 DOI: 10.1007/s00018-014-1667-3]

24 **Sitia G**, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, Esposito A, Ruggeri ZM, Chisari FV, Iannacone M, Guidotti LG. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. *Proc Natl Acad Sci USA* 2012; **109**: E2165-E2172 [PMID: 22753481 DOI: 10.1073/pnas.1209182109]

25 **Kato S**, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. *Transfusion* 2006; **46**: 1444-1452 [PMID: 16934083 DOI: 10.1111/j.1537-2995.2006.00914.x]

26 **Matsumoto M**, Kawaguchi S, Ishizashi H, Yagi H, Iida J, Sakaki T, Fujimura Y. Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. *Pathophysiol Haemost Thromb* 2005; **34**: 35-40 [PMID: 16293984 DOI: 10.1159/000088546]

27 **Kanda Y**. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant* 2013; **48**: 452-458 [PMID: 23208313 DOI: 10.1038/bmt.2012.244]

28 **Nierodzik ML**, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. *Cancer Res* 1992; **52**: 3267-3272 [PMID: 1596884 DOI: 10.1016/0304-3835(92)90079-B]

29 **Snyder KM**, Kessler CM. The pivotal role of thrombin in cancer biology and tumorigenesis. *Semin Thromb Hemost* 2008; **34**: 734-741 [PMID: 19214911 DOI: 10.1055/s-0029-1145255]

30 **Guo R**, Yang J, Liu X, Wu J, Chen Y. Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer. *J Clin Lab Anal* 2018; **32** [PMID: 28374895 DOI: 10.1002/jcla.22219]

31 **Lencioni R**, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis* 2010; **30**: 52-60 [PMID: 20175033 DOI: 10.1055/s-0030-1247132]

32 **Lee M**, Chung GE, Lee JH, Oh S, Nam JY, Chang Y, Cho H, Ahn H, Cho YY, Yoo JJ, Cho Y, Lee DH, Cho EJ, Yu SJ, Lee DH, Lee JM, Kim YJ, Yoon JH. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. *Hepatology* 2017; **66**: 1556-1569 [PMID: 28617992 DOI: 10.1002/hep.29318]

33 **Kanthaje S**, Makol A, Chakraborti A. Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks. *Hepatol Res* 2018; **48**: 5-14 [PMID: 29055114 DOI: 10.1111/hepr.12991]

34 **Pépin M**, Kleinjan A, Hajage D, Büller HR, Di Nisio M, Kamphuisen PW, Salomon L, Veyradier A, Stepanian A, Mahé I. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. *J Thromb Haemost* 2016; **14**: 306-315 [PMID: 26589836 DOI: 10.1111/jth.13205]

35 **Yang X**, Sun HJ, Li ZR, Zhang H, Yang WJ, Ni B, Wu YZ. Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. *BMC Cancer* 2015; **15**: 80 [PMID: 25886574 DOI: 10.1186/s12885-015-1083-6]

36 **Enooku K**, Kato R, Ikeda H, Kurano M, Kume Y, Yoshida H, Ono T, Aizawa K, Suzuki T, Yamazaki T, Yatomi Y. Inverse correlations between serum ADAMTS13 levels and systolic blood pressure, pulse pressure, and serum C-reactive protein levels observed at a general health examination in a Japanese population: a cross-sectional study. *Clin Chim Acta* 2013; **421**: 147-151 [PMID: 23523588 DOI: 10.1016/j.cca.2013.03.012]

**P-Reviewer:** Hu X, Raffaniello R, Saglam S **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Oncology

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Characteristics of patients with hepatocelullar carcinoma receiving sorafenib treatment according to treatment outcomes**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Total****(*n* = 41)** | **SD + PR + CR****(*n* = 17)** | **PD****(*n* = 24)** | ***P* value** |
| Age (yr) | 74.0 (69.0-81.0) | 74.0 (71.0-78.0) | 74.0 (63.5-70.0) | 0.400 |
| Sex (male/female) | 38/3 | 17/0 | 21/3 | 0.254 |
| Etiology (HBV/HCV/NASH/alcohol) | 7/20/3/11 | 0/13/1/3 | 7/7/2/8 | 0.0707 |
| Albumin (g/dL) | 3.6 (3.3-3.9) | 3.7 (3.5-4.0) | 3.5 (3.3-3.7) | 0.0827 |
| Prothrombin time (%) | 82.0 (77.0-89.0) | 83.0 (78.0-89.0) | 82.0 (78.5-91.0) | 0.751 |
| Total bilirubin (mg/dL) | 0.8 (0.6-0.9) | 0.7 (0.5-0.9) | 0.8 (0.6-0.9) | 0.397 |
| Platelet count (× 104/mm3) | 14.1 (11.1-17.3) | 16.1 (9.4-18.3) | 14.1 (11.6-16.9) | 0.568 |
| AFP (ng/mL) | 121.8 (11.3-2611.0) | 31.8 (6.7-161.0) | 286.0 (41.6-5193.5) | 0.103 |
| DCP (mAU/mL) | 359.5 (58.0-5277.5) | 192 (24.5-5177) | 5177 (183-17214) | 0.012 |
| AFP-L3% (%) | 13.2 (1.7-42.4) | 12.3 (1.45-34.3) | 21.8 (1.85-47.7) | 0.529 |
| VEGF (pg/mL) | 25.8 (14.1-40.1) | 18.5 (10.0-35.1) | 28.2 (22.0-50.7) | 0.106 |
| VEGFR-2 (pg/mL) | 6500 (5750-7400) | 6400 (5200-7100) | 6800 (6350-7600) | 0.211 |
| Maximum tumor size (cm) | 3.3 (2.5-7.7) | 3.2 (2.0-6.0) | 4.3 (2.7-10.8) | 0.220 |
| Tumor number (1/2/3/4 or more/only distant metastasis) | 3/2/1/33/2 | 0/2/1/13/1 | 3/0/0/20/1 | 0.131 |
| PVTT(presence/absence) | 7/34 | 2/15 | 5/19 | 0.679 |
| Distant metastasis(presence/absence) | 17/24 | 10/7 | 7/17 | 0.107 |
| Child-pugh score | 5 (5-6) | 5 (5-6) | 5 (5-6) | 0.469 |
| UICC TNM stage (2/3/4) | 5/16/20 | 1/6/10 | 4/10/10 | 0.455 |
| Observation (survival) period (d) | 328 (156-530) | 564 (405-880) | 162 (116-319) | 0.000322 |

Data are expressed as median (Interquartile range). *P*-values represent comparisons between cirrhotic patients with and without HCC. HCC: Hepatocelullar carcinoma; HCV: Hepatitis C virus; HBV: Hepatitis B virus; NASH: Non-alcoholic steatohepatitis; AFP: Alpha fetoprotein; DCP: Des-γ-carboxy prothrombin; AFP-L3%: *Lens culinaris* agglutinin-reactive alpha-fetoprotein; VEGF: Vascular endothelial growth factor; VEGFR-2: VEGF receptor-2; PVTT: Portal vein tumor thrombosis; UICC: The Union for the International Cancer Control; TNM stage: Tumor-node-metastasis stage; SD: Stable disease; PR: Partial response; CR: Complete response; PD: Progressive disease.

**Table 2 Predictive factors for sorafenib response**

|  |  |  |
| --- | --- | --- |
| **Univariate analysis** | **OR (95%CI)** | ***P* value** |
| Age (per 1 yr increase) | 1.05 (0.967-1.13) | 0.2660  |
| Sex (male *vs* female) | 0.556 (0.0464-6.66) | 0.9950  |
| Viral hepatitis (presence *vs* absence) | 0.527(0.123-2.27) | 0.6430  |
| Albumin (per 1 g/dL decrease) | 6.59 (0.827-52.6) | 0.0750  |
| Prothrombin time (per 1% decrease) | 0.977 (0.928-1.03)  | 0.3910  |
| Total bilirubin (per 1 mg/dL increase) | 0.376 (0.0378-3.74) | 0.4040 |
| Platelet count (per 104/µL decrease) | 1.040 (0.937-1.14) | 0.4970  |
| AFP (per 1 ng/mL increase) | 1.000 (1.000-1.00) | 0.5330  |
| DCP (per 1 mAU/mL increase) | 1.00 (0.999-1.00) | 0.1100  |
| AFP-L3% (per 1% increase) | 1.00 (0.996-1.01) | 0.4420  |
| VEGF (per 1 pg/mL increase) | 0.98 (0.949-1.01) | 0.1950  |
| VEGFR-2 (per 1 pg/mL increase) | 1.00 (0.999-1.000) | 0.2210  |
| Maximum tumor size (per 1 cm increase) | 0.892 (0.752-1.06) | 0.1900  |
| Tumor number (per 1 increase) | 1.11 (0.646-1.90) | 0.7070  |
| PVTT (presence *vs* absence) | 0.835 (0.455-1.53) | 0.5590  |
| Distant metastasis (presence *vs* absence) | 2.450 (0.64-9.37) | 0.1910  |
| ADAMTS13:AC (per 1% increase) | 1.020 (1.0001-1.050) | 0.0039  |
| VWF:Ag (per 1% increase) | 0.996 (0.991-1.000) | 0.0740  |
| VWF:Ag/ADAMTS13:AC (per 1 increase) | 0.465 (0.265-0.817) | 0.0077  |
| Multivariate analysis | 　 | 　 |
| VWF:Ag/ADAMTS13:AC (per 1 increase) | 0.495 (0.281-0.870) | 0.0147  |

AFP: Alpha fetoprotein; DCP: Des-γ-carboxy prothrombin; AFP-L3%: *Lens culinaris* agglutinin-reactive alpha-fetoprotein; VEGF: Vascular endothelial growth factor; VEGFR-2: VEGF receptor-2; PVTT: Portal vein tumor thrombosis; ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF: Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: The ratio of VWF:Ag to ADAMTS13:AC; OR: Odds ratio; CI: Confidence interval.

**Table 3 Prognostic factors for patients with hepatocellular carcinoma receiving sorafenib treatment**

|  |  |  |
| --- | --- | --- |
| **Univariate analysis** | **HR (95%CI)** | ***P* value** |
| Age (per 1 yr increase) | 1.16 (1.032-1.304) | 0.0127  |
| Sex (male *vs* female) | 0.062 (0.000382-1.008) | 0.0561  |
| Viral hepatitis (presence *vs* absence) | 1.416(0.405-4.95) | 0.5862  |
| Albumin (per 1 g/dL decrease) | 0.427 (0.0750-2.44) | 0.3388  |
| Prothrombin time (per 1% decrease) | 1.008 (0.969-1.048)  | 0.3910  |
| Total bilirubin (per 1 mg/dL increase) | 4.203 (0.417-42.30) | 0.2230 |
| Platelet count (per 104/µL decrease) | 0.906 (0.807-1.018) | 0.4970  |
| AFP (per 1 ng/mL increase) | 1.000 (1.000-1.00) | 0.3334  |
| DCP (per 1 mAU/mL increase) | 1.000 (1.000-1.00) | 0.0136  |
| AFP-L3% (per 1% increase) | 0.999 (0.969-1.031) | 0.9484  |
| VEGF (per 1 pg/mL increase) | 0.982 (0.952-1.01) | 0.2426  |
| VEGFR-2 (per 1 pg/mL increase) | 1.00 (0.999-1.000) | 0.8947  |
| Maximum tumor size (per 1 cm increase) | 1.026 (0.868-1.214) | 0.7622  |
| Tumor number (per 1 increase) | 0.751 (0.5-1.129) | 0.1690  |
| PVTT (presence *vs* absence) | 0.347 (0.0384-3.141) | 0.3464  |
| Distant metastasis (presence *vs* absence) | 0.489 (0.129-1.854) | 0.2936  |
| ADAMTS13:AC (per 1% increase) | 0.936 (0.895-0.978) | 0.0035  |
| VWF:Ag (per 1% increase) | 0.996 (0.991-1.000) | 0.9227  |
| VWF:Ag/ADAMTS13:AC (per 1 increase) | 1.33 (0.998-1.772) | 0.0520  |
| Multivariate analysis | 　 | 　 |
| ADAMTS13:AC (per 1% increase) | 0.937 (0.895-0.980) | 0.0045  |

HCC: Hepatocellular carcinoma; AFP: Alpha fetoprotein; DCP: Des-γ-carboxy prothrombin; AFP-L3%: *Lens culinaris* agglutinin-reactive alpha-fetoprotein; VEGF: Vascular endothelial growth factor; VEGFR-2: VEGF receptor-2; PVTT: Portal vein tumor thrombosis; ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: The ratio of VWF:Ag to ADAMTS13:AC; HR: Hazard ratio; CI: Confidence interval.



**Figure 1 Plasma ADAMTS13:AC and VWF:Ag levels in patients with hepatocellular carcinoma** **receiving sorafenib treatment.** A:ADAMTS13:AC level was significantly higher in patients with hepatocellular carcinoma receiving sorafenib treatment who achieved stable disease (SD), partial response (PR), and complete response (CR) than those who achieved progressive disease (PD) (*P <* 0.05); B, C: In contrast, VWF:Ag, and the VWF:Ag/ADAMTS13:AC ratio levels were significantly lower in those with SD, PR, and CR than those with PD (*P <* 0.05, *P <* 0.05). ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: The ratio of VWF:Ag to ADAMTS13:AC; SD: Stable disease; PR: Partial response; CR: Complete response; PD: Progressive disease.



**Figure 2 The relationship between the VWF:Ag/ADAMTS13:AC ratio and tumor-node-metastasis stage.** The VWF:Ag/ADAMTS13:AC ratio level was significantly higher in patients with tumor-node-metastasis stage 4 hepatocellular carcinoma (HCC) than those with stage 2 and 3 HCC.ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: The ratio of VWF:Ag to ADAMTS13:AC; TNM stage: Tumor-node-metastasis stage.



**Figure 3 Diagnostic accuracy of the VWF:Ag/ADAMTS13:AC for sorafenib response.** Thereceiver operating characteristic analysis of the VWF:Ag/ADAMTS13:AC ratio for sorafenib response reveals that a cutoff VWF:Ag/ADAMTS13:AC ratio of 2.609 has a specificity of 84.2% and a sensitivity of 88.2%, with an area under the receiver operating characteristic curve of 0.836. ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: The ratio of VWF:Ag to ADAMTS13:AC.



**Figure 4 Vascular endothelial growth factor is associated with the VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC in patients with hepatocellular carcinoma receiving sorafenib treatment.** A: Hepatocellular carcinoma (HCC) patients with a VWF:Ag/ADAMTS13:AC ratio ≥ 2.609 had significantly higher vascular endothelial growth factor (VEGF) levels than those with a VWF:Ag/ADAMTS13:AC ratio < 2.609; B: HCC patients with an ADAMTS13:AC < 78.0 had significantly higher VEGF levels than those with an ADAMTS13:AC ≥ 78.0. ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: The ratio of VWF:Ag to ADAMTS13:AC; VEGF: Vascular endothelial growth factor.



**Figure 5 ADAMTS13 is associated with progression-free survival and overall survival in patients with hepatocellular carcinoma receiving sorafenib treatment.** Hepatocellular carcinoma (HCC) patients with an ADAMTS13:AC ≥ 78.0 had significantly longer progression-free survival (A) and overall survival (B) than those with an ADAMTS13:AC < 78.0. Solid and dotted lines indicate HCC patients with an ADAMTS13:AC ≥ 78.0 and an ADAMTS13:AC < 78.0, respectively. ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity.